CD38双特异性抗体预靶向放射免疫治疗多发性骨髓瘤及其他B细胞恶性肿瘤
研究开发了一种抗CD38双特异性融合蛋白用于预靶向放射免疫治疗,在骨髓瘤和非霍奇金淋巴瘤小鼠异种移植模型中显示优异的血液清除和肿瘤靶向,最佳剂量下80%小鼠获治愈,疗效等于或优于链霉亲和素-生物素方案。
要点
- CD38双特异性预靶向放射免疫治疗在骨髓瘤和淋巴瘤异种移植模型中第12天达100%完全缓解。
- 最佳剂量下治愈80%小鼠,疗效等于或优于链霉亲和素-生物素CD38方案。
- 双特异性方案降低免疫原性和内源性生物素干扰风险,作者认为是有吸引力的临床转化候选。
核心结论
- CD38双特异性预靶向放射免疫治疗高效且降低免疫原性和内源性生物素干扰风险,作者认为是有吸引力的临床转化候选。
- 作者认为CD38预靶向放射免疫治疗可能不仅延长生存,还可能治愈多发性骨髓瘤和治疗难治性非霍奇金淋巴瘤患者。
研究设计与样本
- 研究开发抗CD38双特异性融合蛋白,在多发性骨髓瘤和非霍奇金淋巴瘤小鼠异种移植模型中进行预靶向放射免疫治疗研究。
主要发现
- 在骨髓瘤和非霍奇金淋巴瘤异种移植模型中,CD38双特异性构建体显示优异的血液清除和肿瘤靶向。
- 剂量学计算显示每毫居里90Y注射剂量肿瘤吸收剂量为43.8 Gy,肿瘤与正常器官剂量比为肝脏7:1、肺和肾脏15:1。
- 治疗研究中,CD38双特异性预靶向放射免疫治疗使骨髓瘤和非霍奇金淋巴瘤异种移植模型第12天达100%完全缓解,最佳剂量下最终治愈80%小鼠。
- 直接比较中,CD38双特异性疗效等于或优于链霉亲和素-生物素CD38预靶向放射免疫治疗;最高辐射剂量1200 µCi下两种方法均治愈至少75%小鼠,600和1000 µCi剂量下双特异性优于链霉亲和素方案,总体多治愈35%小鼠(P < .004)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable efficacy targeting tumor antigens, but immunogenicity and endogenous biotin blocking may limit clinical translation. We describe a new PRIT approach for the treatment of multiple myeloma (MM) and other B-cell malignancies, for which we developed an anti-CD38-bispecific fusion protein that eliminates endogenous biotin interference and immunogenic elements. In murine xenograft models of MM and non-Hodgkin lymphoma (NHL), the CD38-bispecific construct demonstrated excellent blood clearance and tumor targeting. Dosimetry calculations showed a tumor-absorbed dose of 43.8 Gy per millicurie injected dose of 90Y, with tumor-to-normal organ dose ratios of 7:1 for liver and 15:1 for lung and kidney. In therapy studies, CD38-bispecific PRIT resulted in 100% complete remissions by day 12 in MM and NHL xenograft models, ultimately curing 80% of mice at optimal doses. In direct comparisons, efficacy of the CD38 bispecific proved equal or superior to streptavidin (SA)-biotin-based CD38-SA PRIT. Each approach cured at least 75% of mice at the highest radiation dose tested (1200 µCi), whereas at 600- and 1000-µCi doses, the bispecific outperformed the SA approach, curing 35% more mice overall (P < .004). The high efficacy of bispecific PRIT, combined with its reduced risk of immunogenicity and endogenous biotin interference, make the CD38 bispecific an attractive candidate for clinical translation. Critically, CD38 PRIT may benefit patients with unresponsive, high-risk disease because refractory disease typically retains radiation sensitivity. We posit that PRIT might not only prolong survival, but possibly cure MM and treatment-refractory NHL patients.
引用
- Green DJ, O'Steen S, Lin Y, et al. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood. 2017. PMID: 29158362. doi:10.1182/blood-2017-09-807610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。